21 Oct 2016 07:00
Premaitha Health plc
("Premaitha" or the "Company")
Grant of Options
Manchester, UK - 21 October 2016: Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked complete non-invasive prenatal screening system, makes the following announcement:
Grant of share options
The Company has today issued 940,000 options over ordinary shares under the Company's unapproved share option scheme to two employees. The options are exercisable at any time up to 20 October 2026, subject to performance conditions, at a price of 20 pence per share. Following the issue of these options, the Company has 36,785,030 shares under option and a further 40,272,076 shares under warrant.
The issued share capital of the Company comprises 228,163,709 Ordinary Shares of 10p each.
For more information, please contact:
Premaitha Health plc | Tel: +44 (0) 161 667 6865 |
Dr Stephen Little, Chief Executive Office |
|
Barry Hextall, Chief Financial Officer |
|
Joanne Cross, Head of Marketing |
|
investors@premaitha.com |
|
|
|
Cairn Financial Advisers LLP (Nomad) | Tel: +44 (0) 20 7213 0880 |
Liam Murray / James Caithie |
|
|
|
finnCap (Broker) | Tel: +44 (0) 20 7220 0500 |
Adrian Hargrave / Scott Mathieson (Corporate Finance) |
|
Tony Quirke (Corporate Broking) |
|
|
|
Vigo Communications | Tel: +44 (0) 20 7830 9704 |
Ben Simons / Fiona Henson / Antonia Pollock |
|
premaitha@vigocomms.com |
|
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
About Premaitha
Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.
Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE-marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.
Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha's CE-marked complete system enables laboratories and healthcare practitioners to offer an approved, non-invasive prenatal screening solution in-house.
Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.